Clinical trials · Minnesota
Amyloidosis clinical trials in Minnesota
We’re tracking 18 recruiting amyloidosis studies with a site in Minnesota — including Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Minnesota
- NCT07081646RecruitingPhase 1/Phase 2
CAR T cell therapy for AL amyloidosis
This trial tests a CAR T cell therapy that targets two proteins (CD19 and BCMA) on the surface of abnormal plasma cells. It is for people with AL amyloidosis whose disease has come back or did not respond to at least one prior treatment.
Rochester, MinnesotaAges 18 years+ - NCT06034405Recruiting
Checking spine tissue for heart amyloidosis signs
This trial is looking at leftover tissue from past spine surgeries to see if it contains signs of a heart condition called TTR amyloidosis. It may help find people who have this condition early.
Rochester, MinnesotaAges 50 years+ - NCT06465810Recruiting
Observational study for ATTR amyloidosis patients
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
Rochester, MinnesotaAges 18–130 - NCT06563895RecruitingPhase 3
Testing acoramidis to prevent ATTR amyloidosis in gene carriers
This trial tests a daily pill called acoramidis to see if it can prevent ATTR amyloidosis in people who carry a gene mutation but have no symptoms yet. It aims to stop the disease before it starts.
Rochester, MinnesotaAges 18–75 - NCT07052903RecruitingPhase 3
RNA therapy for ATTR amyloidosis with heart involvement
This trial tests an experimental RNA therapy (nucresiran) for people with transthyretin amyloidosis that causes heart problems (cardiomyopathy). It aims to lower the abnormal protein buildup to help heart function.
Rochester, MinnesotaAges 18–85 - NCT07223203RecruitingPhase 3
Study of nucresiran for hereditary nerve condition (hATTR-PN)
This trial tests a new medicine called nucresiran for people with a rare genetic nerve condition (hATTR-PN). The goal is to see if it can slow down or improve nerve damage.
Rochester, MinnesotaAges 18–85 - NCT06355934Recruiting
Observational study of ATTR amyloidosis treatment patterns
This study looks at the health records of people with ATTR amyloidosis to understand how the disease is treated and what happens over time. It helps doctors learn more about this condition so they can improve care.
Eden Prairie, MinnesotaAges Any age - NCT07224672RecruitingPhase 2
Study of a drug combo for newly diagnosed AL amyloidosis
This trial tests a combination of four drugs (belantamab mafodotin, cyclophosphamide, bortezomib, and dexamethasone) for people newly diagnosed with AL amyloidosis who cannot have a stem cell transplant. The goal is to see if this combination is safe and effective at stopping the abnormal proteins from damaging your organs.
Rochester, MinnesotaAges 18 years+ - NCT05898646RecruitingPhase 2
Daratumumab maintenance for AL amyloidosis after initial treatment
This Phase 2 trial studies whether giving daratumumab as ongoing maintenance therapy after your initial AL amyloidosis treatment can improve survival. It may help by keeping the disease under control longer after you have responded to induction therapy.
Rochester, MinnesotaAges 18 years+ - NCT06022939RecruitingPhase 3
Comparing chemo plus stem cell transplant to chemo alone for AL amyloidosis
This study tests whether adding a stem cell transplant to standard chemotherapy (Dara-VCD) works better than chemotherapy alone for people newly diagnosed with AL amyloidosis. It aims to find the best way to control the disease and improve outcomes.
Saint Paul, MinnesotaAges 18 years+ - NCT06128629RecruitingPhase 3
A study of NTLA-2001 for transthyretin amyloidosis with heart problems
This study tests a new treatment, NTLA-2001, for people with a type of heart disease called transthyretin amyloidosis with cardiomyopathy. It aims to see if the medicine can help improve heart function and quality of life.
Rochester, MinnesotaAges 18–90 - NCT06158854RecruitingPhase 1/Phase 2
Study of etentamig (ABBV-383) for AL amyloidosis
This study tests a new drug called etentamig (ABBV-383) given through a vein to see if it can control disease activity in people with AL amyloidosis who have already tried other treatments. It may help if your disease has progressed or is not responding well to prior therapies.
Rochester, MinnesotaAges 18 years+ - NCT07216469Recruiting
Heart Stiffness in Amyloidosis: A Study Using MRI
This study uses a special MRI scan to measure how stiff the heart muscle is in people with cardiac amyloidosis. The goal is to better understand the condition and potentially guide future treatments.
Rochester, MinnesotaAges 20 years+ - NCT07218705Recruiting
MCG scan study for cardiac amyloidosis
This study uses a new type of heart scan (MCG) to help understand cardiac amyloidosis. It may help doctors learn more about the condition without needing invasive tests.
Rochester, MinnesotaAges 18 years+ - NCT07583823Recruiting
Higher-Rate Pacing for Heart Amyloid Disease
This study tests whether pacing your heart at a faster rate helps people with cardiac amyloidosis (a condition where abnormal protein builds up in the heart). If you have a pacemaker and cardiac amyloidosis, this research might help doctors understand the best pacing settings for you.
Minneapolis, MinnesotaAges 18 years+ - NCT06679946Enrolling by invitationPhase 3
Study of Vutrisiran for heart condition from TTR amyloidosis
This study tests a drug called vutrisiran for people with a condition called transthyretin amyloidosis that affects the heart. It is for patients who have already been in certain earlier studies of patisiran or vutrisiran.
Rochester, MinnesotaAges 18 years+ - NCT07207811RecruitingPhase 3
Coramitug for heart failure caused by ATTR amyloidosis
This trial tests a new medicine called Coramitug for people with heart failure due to ATTR amyloidosis, a condition where abnormal proteins build up in the heart. The study aims to see if Coramitug can improve heart function and quality of life.
Rochester, MinnesotaAges 18 years+ - NCT07308704Recruiting
Using AI to spot heart muscle disease on echocardiograms
This study at Mayo Clinic is testing an artificial intelligence (AI) tool that analyzes echocardiograms (ultrasound of the heart) to find early signs of four types of heart muscle disease. If the AI flags a high-risk pattern, doctors can learn whether acting on that alert helps catch the condition sooner.
Rochester, MinnesotaAges 18 years+
Where these studies are running in Minnesota
Institutions with a site for the recruiting amyloidosis studies listed above.
- Mayo Clinic · 10 studies
- Clinical Trial Site · 3 studies
- Research Site · 3 studies
- Abbott-Northwestern Hospital
- Fairview Southdale Hospital
- GSK Investigational Site
- Mercy Hospital
- Park Nicollet Clinic - Saint Louis Park
What taking part in a amyloidosis study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Amyloidosis trials in other states
Common questions
- Are there amyloidosis clinical trials in Minnesota?
- Yes. We're currently tracking 18 recruiting amyloidosis studies with a site in Minnesota, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a amyloidosis study in Minnesota?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Minnesota to take part?
- Not necessarily. These studies have a site in Minnesota, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a amyloidosis trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New amyloidosis studies open in Minnesota regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.